Andrew K Joe
Overview
Explore the profile of Andrew K Joe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
4082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schram A, Goto K, Kim D, Macarulla T, Hollebecque A, OReilly E, et al.
N Engl J Med
. 2025 Feb;
392(6):566-576.
PMID: 39908431
Background: Neuregulin 1 () fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and...
2.
Marabelle A, Le D, Ascierto P, Di Giacomo A, De Jesus-Acosta A, Delord J, et al.
J Clin Oncol
. 2019 Nov;
38(1):1-10.
PMID: 31682550
Purpose: Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential neoantigens. Such...
3.
Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J, et al.
J Clin Oncol
. 2018 Dec;
37(4):318-327.
PMID: 30557521
Purpose: Biomarkers that can predict response to anti-programmed cell death 1 (PD-1) therapy across multiple tumor types include a T-cell-inflamed gene-expression profile (GEP), programmed death ligand 1 (PD-L1) expression, and...
4.
Joe A, Schnoll-Sussman F, Bresalier R, Abrams J, Hibshoosh H, Cheung K, et al.
Cancer Prev Res (Phila)
. 2015 Oct;
8(12):1131-7.
PMID: 26471236
This study was conducted to determine the safety and efficacy of the green tea-derived Polyphenon E (Poly E) in patients with Barrett's Esophagus (BE). Subjects were randomized to a 6-month,...
5.
Goldinger S, Rinderknecht J, Dummer R, Kuhn F, Yang K, Lee L, et al.
Pharmacol Res Perspect
. 2015 Mar;
3(2):e00113.
PMID: 25729580
Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation-positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination,...
6.
Ribas A, Zhang W, Chang I, Shirai K, Ernstoff M, Daud A, et al.
J Clin Pharmacol
. 2013 Dec;
54(4):368-74.
PMID: 24374975
Vemurafenib is an orally bioavailable BRAF inhibitor approved for the treatment of BRAF(V600) -mutant metastatic melanoma. It is important to understand the effects of a high-fat meal on the pharmacokinetics...
7.
Trunzer K, Pavlick A, Schuchter L, Gonzalez R, McArthur G, Hutson T, et al.
J Clin Oncol
. 2013 Apr;
31(14):1767-74.
PMID: 23569304
PURPOSE To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib...
8.
Lacouture M, Duvic M, Hauschild A, Prieto V, Robert C, Schadendorf D, et al.
Oncologist
. 2013 Mar;
18(3):314-22.
PMID: 23457002
Background: Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs)...
9.
Masuda M, Toh S, Wakasaki T, Suzui M, Joe A
Mol Oncol
. 2012 Nov;
7(1):14-28.
PMID: 23168041
Despite recent advancements in multidisciplinary treatments, the overall survival and quality of life of patients with advanced head and neck squamous cell carcinoma (HNSCC) have not improved significantly over the...
10.
Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J, et al.
N Engl J Med
. 2012 Feb;
366(8):707-14.
PMID: 22356324
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF...